Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995

被引:78
作者
Broers, B
Junet, C
Bourquin, M
Déglon, JJ
Perrin, L
Hirschel, E
机构
[1] Univ Hosp, Div Malad Infect, CH-1205 Geneva, Switzerland
[2] Univ Hosp, Virol Lab, Geneva, Switzerland
[3] Phenix Fdn, Geneva, Switzerland
关键词
HIV; hepatitis B; hepatitis C; drug user; methadone maintenance; prevalence; incidence; Switzerland;
D O I
10.1097/00002030-199815000-00018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate the prevalence and incidence rates of infection with HIV, hepatitis B (HBV) and hepatitis C (HCV), in a cohort of drug users (DU) in Geneva, Switzerland. Design: Prospective open cohort study. Setting: Private methadone maintenance treatment (MMT) programme. Patients, participants: Over 700 DU in treatment between 1988 and 1995 were tested biannually for HIV, HBV and HCV infection. Intervention: None. Main outcome measure: Prevalence for HIV, HBV and HCV at study entry, determined by gender, by injection behaviour, by year of start of MMT and incidence rates for HIV, HBV and HCV, assuming equal risk of seroconversion on each day of the interval between last negative and first positive test. Results: The prevalence at entry into treatment declined dramatically over time for all three viruses. Comparing DU entering treatment before 1988 to those entering treatment after 1993, the prevalence of HIV was 38.2% versus 4.5%, of HBV 80.5% versus 20.1%, and of HCV 91.6% versus 29.8%, respectively. Follow-up rate was 80%. The incidence rates for HIV and HBV were 0.6% and 2.1% per person-year of follow-up, respectively. For HCV the rate was higher (4.2%) especially among women (9.6%). Conclusion: These data suggest that DU have changed HIV risk-taking behaviour in response to HIV prevention campaigns. Current prevention efforts should focus on improvement of HCV prevention, identification of high-risk individuals and maintaining safe behaviour. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:2059 / 2066
页数:8
相关论文
共 26 条
  • [1] HOW EFFECTIVE ARE RISK-REDUCTION INTERVENTIONS TARGETING INJECTING DRUG-USERS
    BOOTH, RE
    WATTERS, JK
    [J]. AIDS, 1994, 8 (11) : 1515 - 1524
  • [2] BRESLOW NE, 1987, STAT METHODS CANC RE, V2, P70
  • [3] HIV AND HARM REDUCTION FOR INJECTION-DRUG USERS
    BRETTLE, RP
    [J]. AIDS, 1991, 5 (02) : 125 - 136
  • [4] BROERS B, 1994, MED HYG, P2162
  • [5] DESJARLAIS DC, 1992, BRIT J ADDICT, V87, P347
  • [6] INTERNATIONAL EPIDEMIOLOGY OF HIV AND AIDS AMONG INJECTING DRUG-USERS
    DESJARLAIS, DC
    FRIEDMAN, SR
    CHOOPANYA, K
    VANICHSENI, S
    WARD, TP
    [J]. AIDS, 1992, 6 (10) : 1053 - 1068
  • [7] DUBOISARBER F, 1993, 82 CAH RECH
  • [8] PREVALENCE OF HIV INFECTION AMONG INTRAVENOUS DRUG-USERS IN THE UNITED-STATES
    HAHN, RA
    ONORATO, IM
    JONES, TS
    DOUGHERTY, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (18): : 2677 - 2684
  • [9] HUNTER GM, 1995, AIDS, V9, P493, DOI 10.1097/00002030-199509050-00012
  • [10] HIV/AIDS-RELATED BEHAVIOR-CHANGE AMONG INJECTING DRUG-USERS IN DIFFERENT NATIONAL SETTINGS
    JARLAIS, DCD
    FRIEDMAN, SR
    FRIEDMANN, P
    WENSTON, J
    SOTHERAN, JL
    CHOOPANYA, K
    VANICHSENI, S
    RAKTHAM, S
    GOLDBERG, D
    FRISCHER, M
    GREEN, S
    LIMA, ES
    BASTOS, FI
    TELLES, PR
    [J]. AIDS, 1995, 9 (06) : 611 - 617